RNTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Rein Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$0.55−0.04 (-6.49%)
Close on Oct 19, 2026
- Market cap
- $37.03M
- P/E (TTM)
- –
- Dividend yield
- 0.00%
Dividends
Rein Therapeutics has not reported a dividend
No dividend per share appears in Rein Therapeutics's annual filings since fiscal 2014.